As AI-driven medical technologies are taking root in the healthcare landscape, regulatory frameworks evolve to keep pace. The EU AI Act introduced new requirements that will shape how AI-powered medical devices are developed, tested, and brought to market. This session will examine the impacts of this new implementation, as well as those we can foresee. How do regulatory bodies, medical devices manufacturers and suppliers face these significant challenges? How are they navigating compliance? How can different stakeholders participate in shaping discussions with regulatory bodies?
EU AI Act: Impacts and future challenges to address
Moderated roundtable discussion consisting in an exchange of ideas and perspectives by international experts to delve into the latest challenges of the sector.
- 11:30 AM
- 12:30 PM
Session that comprises a series of illustrative stories or cases followed by Q&As from the moderator and the audience.
Case studies
- Susie A. Ruff, Founder & CEO, RUFF & CO.
- Marco Caproni, Global Director Software Product Assessment, TÜV SÜD
- David Blanquez, CEO, MJN Neuroserveis
- Quentin Merceron, Digital Venture Architect, Hartmann
- Jessica Garestier, Counsel Life Sciences, Dentons
